Home

THIS MONTH’S FEATURED ARTICLE

Axumin PET Scans and Recurrent Prostate Cancer

Nishant Verma, MD

Axumin™ (Fluciclovine F18) is a new FDA-approved, Medicare-covered diagnostic agent that can achieve early detection of recurrent prostate cancer. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated PSA levels following prior treatment. Read More.